Literature DB >> 12871686

Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil.

Hitoshi Matsuo1, Sachiro Watanabe, Tomonori Segawa, Shinji Yasuda, Takeshi Hirose, Makoto Iwama, Shinichiro Tanaka, Takahiko Yamaki, Yukihiko Matsuno, Masaaki Tomita, Shinya Minatoguchi, Hisayoshi Fujiwara.   

Abstract

BACKGROUND: It is not known whether pretreatment with nicorandil, an ATP-sensitive K+ channel (K(ATP)channel) opener, induces a preconditioning effect independent of increased collateral recruitment.
METHODS: Forty-four patients with angina who underwent percutaneous transluminal coronary angioplasty (PTCA) to proximal left anterior descending artery (LAD) stenosis were randomly allocated for pretreatment with an intravenous injection of 80 g/kg nicorandil 5 min before initial ballooning (n=22) or saline (n=22). 99mTc tetrofosmin was injected during balloon inflation, quantitative analysis of occlusion images by SPECT was conducted, and the defect severity score (SS) was calculated. An ECG was recorded during the 2-min inflation to calculate the sum of ST elevation (sigmaST).
RESULTS: SigmaST levels were significantly reduced in patients with nicorandil pretreatment compared with control patients (control:1.89+/-0.85 mV nicorandil:1.24+/-0.57 mV, p=0.0052). However, no difference was observed in defect severity (control: 79.0+/-32.5, nicorandil: 98.7+/-48.9 ns). A close correlation was observed between SS and sigmaST in both groups (nicorandil group R(2)=0.505, control group R(2)=0.599). A multivariate regression model demonstrated that both defect severity (p<0.0001) and pretreatment with nicorandil (p<0.001) were significantly related to the level of sigmaST, suggesting a cellular protective effect against ischaemia by nicorandil, independent of myocardial blood flow.
CONCLUSION: Nicorandil pretreatment resulted in the induction of myocardial preconditioning independent of the severity of ischaemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871686     DOI: 10.1016/s0195-668x(03)00202-1

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  10 in total

Review 1.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

Review 2.  Use of nicorandil in cardiovascular disease and its optimization.

Authors:  Shigeo Horinaka
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

3.  Nicorandil increased the cerebral blood flow via nitric oxide pathway and ATP-sensitive potassium channel opening in mice.

Authors:  Masakazu Kotoda; Tadahiko Ishiyama; Kazuha Mitsui; Sohei Hishiyama; Takashi Matsukawa
Journal:  J Anesth       Date:  2018-03-05       Impact factor: 2.078

4.  Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits.

Authors:  Xian-Liang Tang; Yu-Ting Xuan; Yanqing Zhu; Gregg Shirk; Roberto Bolli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-12-18       Impact factor: 4.733

Review 5.  Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients.

Authors:  Dene Simpson; Keri Wellington
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Recurrent angina after coronary angioplasty: mechanisms, diagnostic and therapeutic options.

Authors:  Paolo Izzo; Andrea Macchi; Luisa De Gennaro; Antonio Gaglione; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-06

Review 7.  Preconditioning in humans.

Authors:  Shereif H Rezkalla; Robert A Kloner
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

8.  Nicorandil was an Effective Treatment Option for a Patient with Bland-White-Garland Syndrome.

Authors:  Shun Morishita; Hirofumi Maeba; Kazuya Takehana; Ichiro Shiojima
Journal:  Intern Med       Date:  2017-08-10       Impact factor: 1.271

9.  Meta-analysis of Nicorandil effectiveness on myocardial protection after percutaneous coronary intervention.

Authors:  Xiao-Tao Zhao; Chun-Fei Zhang; Qing-Jie Liu
Journal:  BMC Cardiovasc Disord       Date:  2019-06-14       Impact factor: 2.298

Review 10.  Effects of mitochondrial ATP-sensitive potassium channel activation (nicorandil) in patients with angina pectoris undergoing elective percutaneous coronary interventions: A meta-analysis of randomized controlled trials.

Authors:  Houyong Zhu; Xiaoqun Xu; Xiaojiang Fang; Jianwu Zheng; Tielong Chen; Jinyu Huang
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.